創薬流通市場「薬市楽座」
安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。
創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。
なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。
| 掲載日 | シーズ番号 | 作用機序 | 適応症 | 投与経路 | モダリティ | 開発ステージ | 備考 | |
|---|---|---|---|---|---|---|---|---|
| 19/09/30 | GEM107 | Chondrocytes for hyaline cartialge regeneration. | Articular cartilage defects | Refer to Note | Cell Therapy |
Launch | Route: Interventional/ Implantation Note: Live cultured chondrocytes indicated for hyaline cartilage reneration in cartilage injuries. Over 600 pateints treated with several publications and patent protection. |
問合せ |
| 19/09/30 | GEM106 | Osteoblasts for bone regeneration | Refer to Note | Refer to Note | Cell Therapy |
Launch | Indication: Avascular necrosis/Osteonecrosis Route: Interventional/ Implantation Note: Live cultured osteoblasts indicated for bone repair and regeneration that stop progression of avascular necrosis. Over 400 pateints treated with GEM106. Potential label extension to different indications. This product has been granted Orphan Designation by the US FDA & EMA. |
問合せ |
| 19/09/24 | GEM105 | Viscosupplementation | Knee osteoarthritis | Intra-articular | Polysaccharide |
NDA application | Cross-linked sodium hyaluronate hydrogel with sodium hyaluronate fluid. Long lasting and sustainbale efficacy due to unique rheology of the cross-linked hydrogel. Injected only once and single injection shows comparable efficacy to a multiple-injection treatment. Phase-III clinical trial has been finished and NDA application has been submitted. | 問合せ |
| 19/09/12 | GEM104 | Interleukin-1 beta inhibition | Refer to Note | Oral | Small molecule |
Preclinical | Indication: Various types of colitis (IBD, immune-related and chemotherapy-induced colitis) Note: -A known approved drug molecule developed for new therapeutic indications of treating and alleviating symptoms of various types of colitis. -Showed greater pharmacological effects than the reference drug, mesalazine, in reducing inflammatory colon swelling and intestinal ulceration, while restoring damaged intestinal membrane. -One of few products capable of repairing damaged intestine membrane caused by colitis. -Synergistic effect via different mechanism of actions, can provide greater medical benefits to patients suffering from IBD or various types of colitis caused by cancer treatment with chemo- or immuno-therapy. |
問合せ |
| 19/09/03 | GEM103 | Iron chelator | Refer to Note | Oral | Small molecule |
Phase 2 ready for TBI and Phase 1 ready for AMD | Indication: Neurodegenerative and ophthalmologic diseases including traumatic brain injury (TBI) and AMD as lead indications. Additional indications in PD and ALS Note: Novel oral iron chelator with excellent PK and ability to penetrate the brain and retina. Non-protein bound or "free" iron has been demonstrated to be deeply involved in neurodegenerative and ophthalmologic diseases, yet optimal chelators are not available. GEM103 efficiently removes free iron from the brain and retina. Biomarkers to guide drug development are available for both TBI and AMD. Phase 1 trials have been completed for transfusion-related iron-overload. Chronic toxicology completed. |
問合せ |
| 19/08/21 | GEM102 | Cyclodextrin derivative | Cancer | i.v. | Small molecule |
Preclinical | Modified Methyl-b-Cyclodextrin (CyD). Displayed potent antitumor activity in vitro, compared to M-β-CyD. Drastically inhibited tumor growth after a single intravenous injection to tumor-bearing mice, compared to doxorubicin and M-β-CyD, without any significant change in blood chemistry values. |
問合せ |
| 19/08/16 | GEM101 | Positive allosteric modulator of GABA-A receptor | Depression and PTSD | Intra-nasal | Peptide |
Preclinical | Exhibited robust mixed anxiolytic and antidepressant activity in vivo animal models. Increased neurogenesis 1 week after single injection. No decrease in locomotor activity, no sedation. |
問合せ |
| 19/08/16 | GEM100 | mGluR5 negative allosteric modulator | Depression and movement disorder | Intra-nasal | Peptide |
Preclinical | mGLuR5 leader peptide was discovered and in vivo efficacy confirmed. GEM100 specifically increases locomotor activity in rats, with no effects on behavior. |
問合せ |
| 19/08/16 | GEM099 | TrkB modulator | Depression | Intra-nasal | Peptide |
Preclinical | TrkB peptide modulator discovery was launched. | 問合せ |
| 19/08/13 | GEM098 | GnRH receptor antagonist | Endometriosis and Uterine fibroids | Oral | Small molecule |
Phase 1 | In Phase Ib, GEM098 showed dose-dependent suppression of LH, FSH and E2. The suppressive effects on E2 lasted up to 24 hrs and were more excellent when compared with the published phase 1 data of Elagolix in healthy premenopausal women. No serious adverse events were seen and well tolerated up to 320 mg QD. | 問合せ |